Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing

NCT07251049 | Recruiting

• 1 other identifier: PAP_RI2_2019/10
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

: Encephalitis or myelitis is defined as the inflammatory or infectious involvement of the cerebral parenchyma or spinal cord. When an infectious origin is suspected, the germ is not always identified. Next-generation sequencing could be used to correct an etiological diagnosis of these severe conditions in Guadeloupe. The rate of cases for which the infectious agent is not identified encourages continued diagnostic efforts, with the objective of identifying new pathogens or emerging pathogens, some of which may be more specific in the tropics.

Conditions

Acute Encephalitis; Acute Myelitis

Keywords

Acute Infectious encephalitis; myelitis; next generation sequencing; French West Indies

Outcome Measures

Primary Outcomes (1)

• neurotropic pathogen

  The detection of a neurotropic pathogen in the cerebrospinal fluid

  baseline, 3 month (if necessary)

Secondary Outcomes (5)

• Neuro radiological

  baseline, 3 month, 12 month

• Bacteriological

  baseline, 15 days , 3 months

• biochimical

  baseline, 15 days, 3 months

• Clinical neurological

  at day 0, at hospital discharge or maximum on the 15th day (+/- 30 days), and 3 months, 12 months

• • Neuropsychological

  3 months, 12 months

Study Arms (1)

Encephalitis or myelitis

Patients diagnosed with encephalitis or myelitis are defined as having an inflammatory or infectious involvement of the cerebral parenchyma or the spinal cord.

Eligibility Criteria

• Age: 28 Days+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with suspected acute infectious encephalitis and / or myelitis, according to the clinical and paraclinical criteria described in recommendations of the International Encephalitis Consortium in 2013 and the by the Transverse Myelitis Consortium Working Group in 2002

You may qualify if:

• We selected the following eligibility criteria for patients with acute encephalitis:
• Patient of at least 28 days of life
• With acute onset of symptoms for more than 24 hours
• A major criterion among the following:
• a disorder of consciousness or alertness
• memory disorder
• lethargy
• modification of personal or behavioral disorder, irritability
• confusion, disorientation in time or space
• \- At least two of the following minor criteria:
• temperature above 38 ° C
• new onset focal neurological deficit
• epileptic crisis
• biological abnormality of CSF (≥ 5 Leukocytes / mm3, protein ≥ 0.40 g / L)
• partial or general epileptic seizure (s) not attributable to pre-existing epileptic disease and / or a recent focal neurological symptom

You may not qualify if:

• Primary vasculitis of the central nervous system or a documented specific impairment in an autoimmune condition
• Cerebral thrombophlebitis if not associated with encephalitis
• Meningitis without clinical or paraclinical argument for cerebral parenchymal involvement
• Pyogenic abscess
• Cerebral or spinal abscess
• Tumoral or hematological pathology of the central nervous system
• Toxic or metabolic encephalopathy
• Transverse myelitis with vascular or traumatic origin
• Known chronic infection with HTLV virus

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Guadeloupe: lead

Study Sites (1)

Centre Hospitalier Universitaire de la Guadeloupe

Pointe-à-Pitre, Guadeloupe, 97159, Guadeloupe

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

cerebrospinal fluid, blood, urinary

MeSH Terms

Conditions

Myelitis

Condition Hierarchy (Ancestors)

Central Nervous System Infections; Infections; Central Nervous System Diseases; Nervous System Diseases; Spinal Cord Diseases; Neuroinflammatory Diseases

Study Officials

• Hugo CHAUMONT, Doctor

  CHU de la Guadeloupe

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Val"érie HAMONY-SOTER

CONTACT

+590 590 93 46 77; valerie.soter@chu-guadeloupe.fr

Eunice NUBRET

CONTACT

0590934686; eunice.nubret@chu-guadeloupe.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2025
• First Posted: November 26, 2025
• Study Start: November 16, 2023
• Primary Completion (Estimated): November 16, 2028
• Study Completion (Estimated): November 16, 2028
• Last Updated: November 26, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

GU (1)